Beta Bionics, Inc. Common Stock (BBNX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $826.92M
Last updated: Nov 17, 2026 at 4:15 PM ET
Beta Bionics, Inc. Common Stock (BBNX) Statistics
Beta Bionics, Inc. Common Stock (BBNX) has a market cap of $826.92M and an enterprise value of $750.02M. It kept -65.31% of revenue as net income over the last 12 months. Revenue grew 43.69% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 9.30% below the market cap, as cash exceeds debt.
| Market Cap | $826.92M |
|---|---|
| Enterprise Value | $750.02M |
| Latest price (Nov 17, 2026) | $14.72 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 27, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.4x and 1.7x.
| P/S Ratio | 5.4x |
|---|---|
| Forward P/S | 6.6x |
| P/B Ratio | 1.7x |
Price Statistics
The stock is down 45.84% over 52 weeks and trades 19.52% below its 50-day average.
| Beta (1Y) | 1.51 |
|---|---|
| 52-Week Change | -45.84% |
| 1-Month Change | -12.59% |
| 3-Month Change | -26.44% |
| 6-Month Change | +56.26% |
| Total Return (1Y) | -45.84% |
| Return vs SPY (1Y) | -57.26% |
| Max Drawdown (1Y) | -72.30% |
| Sharpe Ratio (1Y) | -0.69 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $18.29 |
| 200-Day Average | $14.83 |
| 52-Week Range | $8.80 to $32.71 |
| RSI (14 Days) | 39.5 |
| Average Volume (20 Days) | 1.17M |
Financial Position
Current assets cover 8.92x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 8.92x |
|---|---|
| Quick Ratio | 8.22x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -18.01% and return on equity is -20.71% over the last 12 months.
| Return on Equity (ROE) | -20.71% |
|---|---|
| Return on Assets (ROA) | -18.73% |
| Return on Invested Capital (ROIC) | -18.01% |
| Asset Turnover | 0.33x |
| Inventory Turnover | 2.25x |
| Receivables Turnover | 6.57x |
| Cash Conversion Cycle | 183 days |
Scores
BBNX has an Altman Z-Score of 8.62, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.62 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $127.27M over the last 12 months.
| Revenue | $127.27M |
|---|---|
| Revenue Growth (YoY) | +43.69% |
| Gross Profit | $74.61M |
| Operating Income | -$92.58M |
| Pretax Income | -$83.11M |
| Net Income | -$83.12M |
| Reported EPS (TTM) | -$1.71 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.45% of the $443.76M in total assets.
| Cash and Equivalents | $81.55M |
|---|---|
| Total Debt | $4.65M |
| Net Cash | $76.90M |
| Net Cash Per Share | $1.65 |
| Working Capital | $260.11M |
| Shareholder Equity | $401.38M |
| Book Value Per Share | $8.62 |
| Total Assets | $443.76M |
| Total Liabilities | $42.38M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $6.59M of capital spending, operating cash flow left -$65.96M of free cash flow.
| Operating Cash Flow | -$59.37M |
|---|---|
| Capital Expenditures | $6.59M |
| Free Cash Flow | -$65.96M |
| FCF Per Share | -$1.22 |
| Depreciation and Amortization | $4.64M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -72.75%.
| Gross Margin | 58.63% |
|---|---|
| Operating Margin | -72.75% |
| Pretax Margin | -65.31% |
| Net Margin | -65.31% |
| FCF Margin | -51.83% |
Dividends and Yields
BBNX does not pay a dividend. Its free cash flow yield is -9.63%.
| FCF Yield | -9.63% |
|---|---|
| Buyback Yield | -24.10% |
| Shareholder Yield | -24.10% |
Peer Position
Against 12 similar companies, BBNX has the 4th highest P/S.
P/S RatioPeer median 3.3x
ROICPeer median -6.00%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +14.00%
| P/S Ratio | 5.4x vs 3.3x median |
|---|---|
| ROIC | -18.01% vs -6.00% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +43.69% vs +14.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BBNX
What is BBNX's market cap?
Beta Bionics, Inc. Common Stock has a market cap of $826.92M. Its enterprise value, which adds debt and subtracts cash, is $750.02M.
How many shares of BBNX are outstanding?
Beta Bionics, Inc. Common Stock has 46.54M shares outstanding. The count is up 6.66% from a year earlier.
Does BBNX pay a dividend?
No. Beta Bionics, Inc. Common Stock does not pay a dividend.
How much debt does BBNX have?
Beta Bionics, Inc. Common Stock has $4.65M of total debt and $81.55M of cash and equivalents, a net cash position of $76.90M.
BBNX pages: Overview, Earnings, Forecast, Financials, Statistics, Competitors